WHO releases priorities for research and development of age-appropriate antibiotics

  28 March 2023

WHO launches today the first ever list of priority paediatric formulations for antibiotics so that more targeted research and development efforts can address the specific needs of infants and children. The scope of this work was to identify antibiotics with an approved paediatric indication for which age-appropriate formulations are missing and that need to be given priority for development. These antibiotics are in the PAediatric Drug Optimization (PADO) priority list and paediatric formulations should be investigated and developed with a time horizon of 3-5 years. The exercise also identified antibiotics under clinical development or approved antibiotics without a pediatric indication to be given priority for further development in children. These antibiotics are in the PADO watch list, and pediatric indications should be studied with a time horizon of 5-10 years.

Further reading: WHO
Author(s): WHO
Kids and Carers   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed